We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+11.82%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$328M
AUM Growth
+$81.1M
Cap. Flow
+$76.2M
Cap. Flow %
23.2%
Top 10 Hldgs %
53.81%
Holding
97
New
24
Increased
8
Reduced
15
Closed
50

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.7M
2
ABT icon
Abbott
ABT
+$18.5M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$17.3M
4
CTLT
CATALENT, INC.
CTLT
+$13.9M
5
ARKK icon
ARK Innovation ETF
ARKK
+$13.4M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.1M
2
WST icon
West Pharmaceutical
WST
+$8.84M
3
APLS
Apellis Pharmaceuticals
APLS
+$8.36M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.85M
5
STVN icon
Stevanato
STVN
+$6.36M

Sector Composition

Rank Sector Weight
1 Healthcare 95.57%
2 Energy 0.07%
3 Real Estate 0.03%
4 Materials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
51
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-17,200
Closed -$889K
ARGX icon
52
argenx
ARGX
$54.8B
– –
-1,299
Closed -$492K
ASND icon
53
Ascendis Pharma A/S
ASND
$16.4B
– –
-99,215
Closed -$12.1M
BMRN icon
54
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-13,100
Closed -$1.36M
BVS icon
55
Bioventus
BVS
$947M
– –
-16,857
Closed -$44K
BYSI icon
56
BeyondSpring
BYSI
$35.8M
– –
-10,833
Closed -$20K
CLDX icon
57
Celldex Therapeutics
CLDX
$3.26B
– –
-176,109
Closed -$7.85M
CRMD icon
58
CorMedix
CRMD
$589M
– –
-13,812
Closed -$58K
DOUG icon
59
Douglas Elliman
DOUG
$163M
– –
-16,574
Closed -$64K
EAF icon
60
GrafTech
EAF
$199M
– –
-1,187
Closed -$56K
GH icon
61
CALL
Guardant Health
GH
$21.1B
– –
-62,600
Closed -$1.7M
GPRO icon
62
GoPro
GPRO
$126M
– –
-16,062
Closed -$80K
HBIO icon
63
Harvard Bioscience
HBIO
$27.9M
– –
-1,003
Closed -$28K
HPP
64
Hudson Pacific Properties
HPP
$729M
– –
-1,632
Closed -$111K
INMD icon
65
InMode
INMD
$869M
– –
-127,242
Closed -$4.54M
IVVD icon
66
Invivyd
IVVD
$194M
– –
-14,967
Closed -$22K
KZR
67
DELISTED
Kezar Life Sciences
KZR
– –
-47,354
Closed -$3.33M
LPRO
68
DELISTED
Open Lending Corp
LPRO
– –
-12,661
Closed -$85K
MBIO icon
69
Mustang Bio
MBIO
$4.36M
– –
-44
Closed -$13K
MTW icon
70
Manitowoc
MTW
$510M
– –
-10,358
Closed -$95K
NGNE icon
71
Neurogene
NGNE
$710M
– –
-512
Closed -$5K
NVCR icon
72
CALL
NovoCure
NVCR
$1.83B
– –
-72,400
Closed -$5.31M
IMDX
73
Insight Molecular Diagnostics
IMDX
$155M
– –
-1,942
Closed -$12K
ORGO icon
74
Organogenesis Holdings
ORGO
$310M
– –
-18,527
Closed -$50K
OVID icon
75
Ovid Therapeutics
OVID
$495M
– –
-10,009
Closed -$19K
1 2
3
4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Tri Locum Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Tri Locum Partners held 97 positions worth $328M, up 33% from $247M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Tri Locum Partners deployed $76.2M of net new capital in Q1 2023, opening 24 new positions and adding to 8 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 91% a quarter earlier, followed by Energy and Real Estate.

On the sell side, the largest reduction was West Pharmaceutical, an estimated $8.84M trimmed.

  • Tri Locum Partners's largest Q1 2023 buy was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.
  • Tri Locum Partners added most to Praxis Precision Medicines in Q1 2023, an estimated $6.93M increase.
  • Tri Locum Partners's biggest Q1 2023 reduction was West Pharmaceutical, cutting an estimated $8.84M.
  • Tri Locum Partners fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $12.1M.
  • Tri Locum Partners's ten largest holdings make up 54% of its $328M portfolio in Q1 2023.
  • Tri Locum Partners opened 24 new positions and closed 50 in Q1 2023.
  • Tri Locum Partners's portfolio value rose 33% quarter-over-quarter to $328M.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.